Bio-Bridge Science Announces $2.775 Million Private Placement

  
    
  
  
    
      Bio-Bridge Science, Inc. (OTCBB:BGES), 
      a biotechnology company engaged in the commercial development of 
      vaccines for the prevention and treatment of human infectious diseases 
      announced today that it had closed a private placement of its investment 
      units. Each investment unit consists of a share of common stock, two 
      series of common stock purchase warrants to purchase 0.5 share of common 
      stock respectively. $2,500,000 of the offering was purchased indirectly 
      by a director, Mr. Trevor Roy. The Company will receive total proceeds 
      of $ 2.775 million. $400,000 was paid at closing, and the balance of 
      $2.375 million will be paid in ten equal amounts in monthly installments 
      until May 1, 2009. The proceeds will be used for general working capital 
      purpose and to fund our vaccine development activities in China.
    
    
      Dr. Liang Qiao, Chairman and CEO of Bio-Bridge said, “We 
      are happy to see our investors strongly support our company and have 
      confidence in our business and strategy. We will see significant 
      business development in both our core business in vaccine development 
      and acquisition/joint venture. We are optimistic that our shareholder 
      value can be maximized through our continuous hard work. ”
    
    
      This press release contains forward-looking statements. Forward-looking 
      statements include statements concerning plans, objectives, goals, 
      strategies, future events or performance, and underlying assumptions and 
      other statements that are other than statements of historical facts. 
      These statements are subject to uncertainties and risks including, but 
      not limited to, product and service demand and acceptance, changes in 
      technology, economic conditions, the impact of competition and pricing, 
      government regulation, and other risks defined in this document and in 
      statements filed from time to time with the Securities and Exchange 
      Commission. All such forward-looking statements, whether written or 
      oral, and whether made by or on behalf of the company, are expressly 
      qualified by these cautionary statements and any other cautionary 
      statements which may accompany the forward-looking statements. In 
      addition, the company disclaims any obligation to update any 
      forward-looking statements to reflect events or circumstances after the 
      date hereof. Please refer to the Company's SEC filings for additional 
      information.